The FDA has approved Hyrnuo for some with locally advanced or metastatic non-squamous non–small cell lung cancer with ...

Just a few months after Boehringer Ingelheim broke into the oncology space with the first drug that can target a rare tumor ...

The accelerated FDA approval of Bayer's Hyrnuo covers treatment of advanced cases of non-small cell lung cancer with HER2 ...

The nod brings Bayer face-to-face in the market with Boehringer Ingelheim and AstraZeneca, each of which has its own HER2 ...

Bayer (OTCPK:BAYRY) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its tyrosine kinase ...

Bayer AG won US approval for its new medicine Hyrnuo to treat a common form of lung cancer as the German company works to bolster its drug pipeline.

FDA grants accelerated approval to Bayer's Hyrnuo and full approval to Amgen's Imdelltra, expanding treatment options for ...

U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous NSCLC ...

FDA fast-tracks Bayer's Hyrnuo, unlocking a potential $800 million market and giving the stock another shot of life ...

The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...

Bayer’s sevabertinib picks up a second-line indication for HER2-mutated disease, joining Boehringer’s zongertinib on the US ...

In patients naïve to HER2-targeted therapy, the objective response rate was 71% with a median duration of response of 9.2 months.